Allergo Journal International publishes a study on Beltavac Depot Plus

The Allergo Journal International has published a study suggesting that Beltavac Depot Plus with mite extract administered in an accelerated cluster schedule is safe and may improve adherence to treatment. 

Approximately 50% of patients treated with allergen immunotherapy fail to complete the required minimum course of treatment of 3 years.

This article suggests that an accelerated cluster schedule is as safe as a standard regimen and could improve adherence to treatment, which is essential for patients with limited access to immunotherapy services.

Click here to read the article.